The global amyotrophic lateral sclerosis treatment market size is estimated to reach USD 987.6 million by 2030, registering a CAGR of 5.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. Some of the key factors driving the market include growing awareness about ALS, increasing incidence rate, and rising geriatric population. However, the cost associated with ALS treatment is high, which may hinder the market growth during the forecast period.
Currently, no cure is available for ALS and treatments such as medications and stem cell therapies can only help to slow down the disease progression, manage the symptoms, and prevent unnecessary complications. Furthermore, inclination towards a sedentary lifestyle among the geriatric population increases the risk of developing the disorder that increases the demand for new targeted treatment options and therapeutic approaches.
Among the treatments, the medications acquired the largest market share in 2023 and is expected to dominate the ALS market over the forecast period. Currently, only two drugs have been approved for use in ALS treatment, Rilutek (riluzole) and Radicava (edaravone). Nuedexta (dextromethorphan/quinidine) in another drug used in ALS treatments, however, it has been approved to treat the pseudobulbar affect (PBA), a comorbidity of ALS. North America held the leading position in the amyotrophic lateral sclerosis market in 2018, while Asia Pacific is projected to grow the fastest among all regions through the forecast period.
Request a free sample copy or view report summary: Amyotrophic Lateral Sclerosis Treatment Market Report
Medications held the largest market share in the treatment segment. Although, there is no cure for ALS, the approved medications such as riluzole and edaravone help in managing symptoms and delaying the disease progression.
Stem cell therapy is expected to demonstrate the highest CAGR among the treatment over the forecast period due to the increasing demand for new approaches and advanced treatment options
Asia Pacific regional market is projected to demonstrate the fastest growth during the forecast period due to rising disposable income and improving healthcare infrastructure
Some of the major companies operating in this market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc.
Grand View Research has segmented the global amyotrophic lateral sclerosis treatment market based on treatment, type, distribution channel, and region:
Amyotrophic Lateral Sclerosis Treatment Treatment Outlook (Revenue, USD Million, 2018 - 2030)
Medication
Riluzole
Edaravone
Others
Stem Cell Therapy
Others
Amyotrophic Lateral Sclerosis Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)
Sporadic ALS
Familial ALS
Amyotrophic Lateral Sclerosis Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Others
Amyotrophic Lateral Sclerosis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Amyotrophic Lateral Sclerosis Treatment Market
Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation)
Biogen
BrainStorm Cell Limited
Amylyx Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Sanofi
Otsuka Pharmaceutical Co., Ltd.
F. Hoffmann-La Roche Ltd
AB Science
Sun Pharmaceutical Industries Ltd.
Orion Corporation
CORESTEMCHEMON Inc.
"The quality of research they have done for us has been excellent..."